中宠股份(002891) - 2020 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2020 was ¥372,870,873.38, a decrease of 2.03% compared to ¥380,599,690.95 in the same period last year[8]. - Net profit attributable to shareholders was ¥8,271,218.87, representing a 20.85% increase from ¥6,844,198.21 year-on-year[8]. - The net profit after deducting non-recurring gains and losses was ¥7,049,741.19, up 28.19% from ¥5,499,364.19 in the previous year[8]. - Basic earnings per share increased to ¥0.0487, a rise of 20.84% from ¥0.0403[8]. - The total comprehensive income increased by 61% compared to the same period last year, driven by an increase in net profit attributable to the parent company[21]. - The company reported a net profit of CNY 264,975,540.46, compared to CNY 256,704,321.60 in the previous year, showing an increase of 3.0%[46]. - The total comprehensive income for Q1 2020 was ¥9,819,347.69, up from ¥6,099,029.63 in Q1 2019, indicating a growth of 61.5%[57]. Cash Flow and Liquidity - The net cash flow from operating activities was -¥25,700,520.24, a decline of 73.99% compared to -¥14,771,574.53 in the same period last year[8]. - Cash and cash equivalents decreased by 61.01% year-on-year, primarily due to a reduction in net cash flow generated from financing activities[22]. - Cash inflow from financing activities totaled CNY 166,871,115.29, down 46.9% from CNY 314,581,444.40 in the previous period[65]. - Cash outflow for investing activities was CNY 36,213,338.03, significantly reduced from CNY 97,789,509.60 in the previous period[64]. - Cash inflow from sales of goods and services was CNY 438,328,431.71, up from CNY 337,292,361.95 in the previous period[62]. - Cash and cash equivalents at the end of the period were CNY 225,506,658.31, down from CNY 261,983,049.22 in the previous period[66]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,867,442,538.05, reflecting a growth of 9.84% from ¥1,700,206,819.50 at the end of the previous year[8]. - Current liabilities increased to CNY 732,682,600.19 from CNY 575,271,261.87, reflecting a significant rise of 27.4%[46]. - The company's inventory increased by 42.65% compared to the beginning of the period, mainly due to an increase in raw material reserves[20]. - Accounts receivable decreased to CNY 194,763,711.82 from CNY 233,958,538.81, indicating a reduction of about 17%[40]. - The company's short-term borrowings rose to CNY 326,753,392.10 from CNY 270,027,470.00, an increase of about 21%[42]. Shareholder Information - The top shareholder, Yantai Zhongxing Biotechnology Co., Ltd., holds 30.46% of the shares, with a total of 51,790,500 shares[11]. - The company reported a total of 12,476 common shareholders at the end of the reporting period[11]. Government and Other Income - The company received government subsidies amounting to ¥414,790.93 during the reporting period[8]. - The company’s other income decreased by 78.77% compared to the same period last year, primarily due to a reduction in government subsidies received[21]. Investment and Expenses - Research and development expenses increased to ¥5,282,931.14, up from ¥4,527,054.49 in the previous year, reflecting a growth of 16.7%[54]. - The company experienced a significant increase in management expenses to ¥18,760,515.73 from ¥14,864,047.35, marking a rise of 26.5%[54]. - Investment losses for Q1 2020 were reported at ¥-1,355,518.57, worsening from ¥-603,553.58 in Q1 2019[54]. Risk Management - The independent directors unanimously agreed to allow the company and its subsidiaries to engage in financial derivative transactions not exceeding USD 40 million, aimed at hedging against currency and interest rate risks[32]. - The company is committed to enhancing its risk management strategies in financial derivative trading to mitigate potential losses from currency fluctuations[32].